{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:29:20Z","timestamp":1793104160630,"version":"4.5.0"},"reference-count":42,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["16685"],"award-info":[{"award-number":["16685"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Familial hypercholesterolemia (FH) is a prevalent and potentially fatal illness\nthat causes a substantial elevation in low-density lipoprotein cholesterol (LDL-C).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A comprehensive search was done on PubMed\/MEDLINE, EMBASE, Web of Science\n(WOS\/ ISI), Scopus, ClinicalTrials (www.ClinicalTrials.gov), and conferences\/ congress research\npapers. Random effect models were used to calculate mean differences (%) and risk ratios (RRs),\nand confidence intervals (95%).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Ten studies (n=1489 patients) were included in this study. PCSK9 inhibitors decreased the\nlevels of LDL-C by -49.59% (95%CI -55.5%, -43.67%) as compared to placebo. They also didn\u2019t\nalter the Treatment-Emergent Adverse Event (TEAE) and neuronal events by RR 0.92 (0.75, 1.13)\nand 1.31 (0.66, 2.59), respectively. PCSK9 inhibitors were effective and safe in treating patients\nwith FH.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>There was high-quality evidence showing that monoclonal antibodies (alirocumab &amp;\nevolocumab) lower LDL-C (GRADE: high), lipoprotein (a) (GRADE: High), triglycerides (TG)\n(GRADE: High), total cholesterol (GRADE: High), non-high-density lipoprotein cholesterol (non-\nHDL-C) (GRADE: Moderate), and apolipoprotein B (GRADE: High), and increase the HDL-C\n(GRADE: High) as well as apolipoprotein A1 (GRADE: High). Comparing PCSK9 inhibitors\nagainst placebo, neither TEAE (GRADE: high) nor neuronal events (GRADE: moderate) were\nchanged.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Registration number:<\/jats:title>\n<jats:p>PROSPERO-CRD42022334035<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867330666230228120601","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T11:16:48Z","timestamp":1677583008000},"page":"223-241","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of Alirocumab and Evolocumab as Proprotein\nConvertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibitors in Familial\nHypercholesterolemia: A Systematic Review and Meta-Analysis"],"prefix":"10.2174","volume":"31","author":[{"given":"Ghasem","family":"Ghasempour","sequence":"first","affiliation":[{"name":"Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago Illnosis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Zamani-Garmsiri","sequence":"additional","affiliation":[{"name":"Department of Clinical\nBiochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Shaikhnia","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of\nMedicine, Uraemia University of Medical Sciences, Uraemia, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Akbar","family":"Soleimani","sequence":"additional","affiliation":[{"name":"Department of Clinical\nBiochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Reza","family":"Hosseini  Fard","sequence":"additional","affiliation":[{"name":"Department of Clinical\nBiochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Leila","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Iran University\nof Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohreh","family":"Teimuri","sequence":"additional","affiliation":[{"name":"Institute of Cell Biology, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najmeh","family":"Parvaz","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry,\nSchool of Medicine, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Mohammadi","sequence":"additional","affiliation":[{"name":"Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago Illnosis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Najafi","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry,\nSchool of Medicine, Iran University of Medical Sciences, Tehran, Iran"},{"name":"Microbial Biotechnology Research Center, Iran University of Medical\nSciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"669","volume":"14","author":"Pejic R.N.","year":"2014","unstructured":"Pejic R.N.; Familial hypercholesterolemia. Ochsner J 2014,14(4),669-672","journal-title":"Ochsner J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/aje\/kwh236","volume":"160","author":"Austin M.A.","year":"2004","unstructured":"Austin M.A.; Hutter C.M.; Zimmern R.L.; Humphries S.E.; Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review. Am J Epidemiol 2004,160(5),407-420","journal-title":"Am J Epidemiol"},{"key":"ref=3","first-page":"53","volume":"3","author":"De Castro-Or\u00f3s I.","year":"2010","unstructured":"De Castro-Or\u00f3s I.; Pocov\u00ed M.; Civeira F.; The genetic basis of familial hypercholesterolemia: Inheritance, linkage, and mutations. Appl Clin Genet 2010,3,53-64","journal-title":"Appl Clin Genet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1515\/jomb-2016-0019","volume":"35","author":"Softanmohammadi E.","year":"2016","unstructured":"Softanmohammadi E.; Piran S.; Mohammadi A.; Hosseni B.; Naseri F.; Shabani M.; Najafi M.; Serum sdLDL-C and cellular SREBP2-dependent cholesterol levels; is there a challenge on targeting PCSK9? J Med Biochem 2016,35(4),410-415","journal-title":"J Med Biochem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fphys.2019.00280","volume":"10","author":"Chen P.","year":"2019","unstructured":"Chen P.; Chen X.; Zhang S.; Current status of familial hypercholesterolemia in China: A need for patient FH registry systems. Front Physiol 2019,10,280","journal-title":"Front Physiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3389\/fphar.2018.00707","volume":"9","author":"Mytilinaiou M.","year":"2018","unstructured":"Mytilinaiou M.; Kyrou I.; Khan M.; Grammatopoulos D.K.; Randeva H.S.; Familial hypercholesterolemia: New horizons for diagnosis and effective management. Front Pharmacol 2018,9,707","journal-title":"Front Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"Stone N.J.","year":"2014","unstructured":"Stone N.J.; Robinson J.G.; Lichtenstein A.H.; Bairey Merz C.N.; Blum C.B.; Eckel R.H.; Goldberg A.C.; Gordon D.; Levy D.; Lloyd-Jones D.M.; McBride P.; Schwartz J.S.; Shero S.T.; Smith S.C.; Watson K.; Wilson P.W.F.; 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014,63(25),2889-2934","journal-title":"J Am Coll Cardiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.amjcard.2014.05.035","volume":"114","author":"Kataoka Y.","year":"2014","unstructured":"Kataoka Y.; Puri R.; Hammadah M.; Duggal B.; Uno K.; Kapadia S.R.; Tuzcu E.M.; Nissen S.E.; Nicholls S.J.; Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy. Am J Cardiol 2014,114(4),549-554","journal-title":"Am J Cardiol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1586\/14779072.6.7.955","volume":"6","author":"Toth P.P.","year":"2008","unstructured":"Toth P.P.; Harper C.R.; Jacobson T.A.; Clinical characterization and molecular mechanisms of statin myopathy. Expert Rev Cardiovasc Ther 2008,6(7),955-969","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","volume":"28","author":"Silva M.A.","year":"2006","unstructured":"Silva M.A.; Swanson A.C.; Gandhi P.J.; Tataronis G.R.; Statin-related adverse events: A meta-analysis. Clin Ther 2006,28(1),26-35","journal-title":"Clin Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40256-013-0053-0","volume":"14","author":"Navarese E.P.","year":"2014","unstructured":"Navarese E.P.; Szczesniak A.; Kolodziejczak M.; Gorny B.; Kubica J.; Suryapranata H.; Statins and risk of new-onset diabetes mellitus: Is there a rationale for individualized statin therapy? Am J Cardiovasc Drugs 2014,14(2),79-87","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ahj.2014.05.004","volume":"168","author":"Blazing MA","year":"2014","unstructured":"Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. Am Heart J 2014,168(2),205-212","journal-title":"Am Heart J"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/cvr\/cvw194","volume":"112","author":"Norata G.D.","year":"2016","unstructured":"Norata G.D.; Tavori H.; Pirillo A.; Fazio S.; Catapano A.L.; Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovasc Res 2016,112(1),429-442","journal-title":"Cardiovasc Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.bbalip.2017.05.002","volume":"1862","author":"Fu T.","year":"2017","unstructured":"Fu T.; Guan Y.; Xu J.; Wang Y.; APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo. Biochim Biophys Acta Mol Cell Biol Lipids 2017,1862(9),883-889","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.5551\/jat.RV17012","volume":"24","author":"Nozue T.","year":"2017","unstructured":"Nozue T.; Lipid lowering therapy and circulating PCSK9 concentration. J Atheroscler Thromb 2017,24(9),895-907","journal-title":"J Atheroscler Thromb"},{"key":"ref=16","first-page":"28","volume":"41","author":"Manniello M.","year":"2016","unstructured":"Manniello M.; Pisano M.; Alirocumab (Praluent): First in the new class of PCSK9 inhibitors. PandT 2016,41(1),28-53","journal-title":"PandT"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","volume":"57","author":"Kasichayanula S.","year":"2018","unstructured":"Kasichayanula S.; Grover A.; Emery M.G.; Gibbs M.A.; Somaratne R.; Wasserman S.M.; Gibbs J.P.; Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet 2018,57(7),769-779","journal-title":"Clin Pharmacokinet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","volume":"51","author":"Verhagen A.P.","year":"1998","unstructured":"Verhagen A.P.; de Vet H.C.W.; de Bie R.A.; Kessels A.G.H.; Boers M.; Bouter L.M.; Knipschild P.G.; The delphi list. J Clin Epidemiol 1998,51(12),1235-1241","journal-title":"J Clin Epidemiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"Wan X.","year":"2014","unstructured":"Wan X.; Wang W.; Liu J.; Tong T.; Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 2014,14(1),135","journal-title":"BMC Med Res Methodol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4103\/2229-3485.100662","volume":"3","author":"Barde P.","year":"2012","unstructured":"Barde P.; Barde M.; What to use to express the variability of data: Standard deviation or standard error of mean? Perspect Clin Res 2012,3(3),113-116","journal-title":"Perspect Clin Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"Egger M.","year":"1997","unstructured":"Egger M.; Smith G.D.; Schneider M.; Minder C.; Bias in meta-analysis detected by a simple, graphical test. BMJ 1997,315(7109),629-634","journal-title":"BMJ"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/0470870168.ch8","author":"Duval S.","year":"2005","unstructured":"Duval S.; The trim and fill method. Publication bias in meta-analysis: Prevention, assessment and adjustments 2005,127-144","journal-title":"Publication bias in meta-analysis: Prevention, assessment and adjustments"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","volume":"336","author":"Guyatt G.H.","year":"2008","unstructured":"Guyatt G.H.; Oxman A.D.; Kunz R.; Vist G.E.; Falck-Ytter Y.; Sch\u00fcnemann H.J.; What is \u201cquality of evidence\u201d and why is it important to clinicians? BMJ 2008,336(7651),995-998","journal-title":"BMJ"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","volume":"76","author":"Blom D.J.","year":"2020","unstructured":"Blom D.J.; Harada-Shiba M.; Rubba P.; Gaudet D.; Kastelein J.J.P.; Charng M.J.; Pordy R.; Donahue S.; Ali S.; Dong Y.; Khilla N.; Banerjee P.; Baccara-Dinet M.; Rosenson R.S.; Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia. J Am Coll Cardiol 2020,76(2),131-142","journal-title":"J Am Coll Cardiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","volume":"30","author":"Ginsberg H.N.","year":"2016","unstructured":"Ginsberg H.N.; Rader D.J.; Raal F.J.; Guyton J.R.; Baccara-Dinet M.T.; Lorenzato C.; Pordy R.; Stroes E.; Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher. Cardiovasc Drugs Ther 2016,30(5),473-483","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"ehv370","DOI":"10.1093\/eurheartj\/ehv370","volume":"36","author":"Kastelein J.J.P.","year":"2015","unstructured":"Kastelein J.J.P.; Ginsberg H.N.; Langslet G.; Hovingh G.K.; Ceska R.; Dufour R.; Blom D.; Civeira F.; Krempf M.; Lorenzato C.; Zhao J.; Pordy R.; Baccara-Dinet M.T.; Gipe D.A.; Geiger M.J.; Farnier M.; ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015,36(43),ehv370","journal-title":"Eur Heart J"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","volume":"37","author":"Moriarty P.M.","year":"2016","unstructured":"Moriarty P.M.; Parhofer K.G.; Babirak S.P.; Cornier M.A.; Duell P.B.; Hohenstein B.; Leebmann J.; Ramlow W.; Schettler V.; Simha V.; Steinhagen-Thiessen E.; Thompson P.D.; Vogt A.; von Stritzky B.; Du Y.; Manvelian G.; Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: The ODYSSEY ESCAPE trial. Eur Heart J 2016,37(48),3588-3595","journal-title":"Eur Heart J"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal F.","year":"2012","unstructured":"Raal F.; Scott R.; Somaratne R.; Bridges I.; Li G.; Wasserman S.M.; Stein E.A.; Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012,126(20),2408-2417","journal-title":"Circulation"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"Raal F.J.","year":"2015","unstructured":"Raal F.J.; Honarpour N.; Blom D.J.; Hovingh G.K.; Xu F.; Scott R.; Wasserman S.M.; Stein E.A.; Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial. Lancet 2015,385(9965),341-350","journal-title":"Lancet"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"Raal F.J.","year":"2015","unstructured":"Raal F.J.; Stein E.A.; Dufour R.; Turner T.; Civeira F.; Burgess L.; Langslet G.; Scott R.; Olsson A.G.; Sullivan D.; Hovingh G.K.; Cariou B.; Gouni-Berthold I.; Somaratne R.; Bridges I.; Scott R.; Wasserman S.M.; Gaudet D.; PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet 2015,385(9965),331-340","journal-title":"Lancet"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein E.A.","year":"2012","unstructured":"Stein E.A.; Gipe D.; Bergeron J.; Gaudet D.; Weiss R.; Dufour R.; Wu R.; Pordy R.; Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet 2012,380(9836),29-36","journal-title":"Lancet"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","volume":"43","author":"Guedeney P.","year":"2022","unstructured":"Guedeney P.; Giustino G.; Sorrentino S.; Claessen B.E.; Camaj A.; Kalkman D.N.; Vogel B.; Sartori S.; De Rosa S.; Baber U.; Indolfi C.; Montalescot G.; Dangas G.D.; Rosenson R.S.; Pocock S.J.; Mehran R.; Efficacy and safety of alirocumab and evolocumab: A systematic review and meta-analysis of randomized controlled trials. Eur Heart J 2022,43(7),e17-e25","journal-title":"Eur Heart J"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11883-002-0058-7","volume":"4","author":"Marais A.D.","year":"2002","unstructured":"Marais A.D.; Blom D.J.; Firth J.C.; Statins in homozygous familial hypercholesterolemia. Curr Atheroscler Rep 2002,4(1),19-25","journal-title":"Curr Atheroscler Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/bcp.13066","volume":"82","author":"Gouni-Berthold I.","year":"2016","unstructured":"Gouni-Berthold I.; Descamps O.S.; Fraass U.; Hartfield E.; Allcott K.; Dent R.; M\u00e4rz W.; Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br J Clin Pharmacol 2016,82(6),1412-1443","journal-title":"Br J Clin Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.18553\/jmcp.2016.22.6.641","volume":"22","author":"McDonagh M.","year":"2016","unstructured":"McDonagh M.; Peterson K.; Holzhammer B.; Fazio S.; A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J Manag Care Spec Pharm 2016,22(6),641-653q","journal-title":"J Manag Care Spec Pharm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.18433\/J36C8N","volume":"20","author":"Eslami S.M.","year":"2017","unstructured":"Eslami S.M.; Nikfar S.; Ghasemi M.; Abdollahi M.; Does evolocumab, as a PCSK9 inhibitor, ameliorate the lipid profile in familial hypercholesterolemia patients? A meta-analysis of randomized controlled trials. J Pharm Pharm Sci 2017,20,81-96","journal-title":"J Pharm Pharm Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e001937","DOI":"10.1161\/JAHA.115.001937","volume":"4","author":"Li C.","year":"2015","unstructured":"Li C.; Lin L.; Zhang W.; Zhou L.; Wang H.; Luo X.; Luo H.; Cai Y.; Zeng C.; Efficiency and safety of proprotein convertase subtilisin\/kexin 9 monoclonal antibody on hypercholesterolemia: A meta-analysis of 20 randomized controlled trials. J Am Heart Assoc 2015,4(6),e001937","journal-title":"J Am Heart Assoc"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40256-018-0303-2","volume":"19","author":"Cao Y.X.","year":"2019","unstructured":"Cao Y.X.; Liu H.H.; Li S.; Li J.J.; A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) levels. Am J Cardiovasc Drugs 2019,19(1),87-97","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s40618-019-01019-4","volume":"42","author":"Dicembrini I.","year":"2019","unstructured":"Dicembrini I.; Giannini S.; Ragghianti B.; Mannucci E.; Monami M.; Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: A systematic review and meta-analysis of randomized controlled trials. J Endocrinol Invest 2019,42(9),1029-1039","journal-title":"J Endocrinol Invest"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e006910","DOI":"10.1161\/JAHA.117.006910","volume":"6","author":"Karatasakis A.","year":"2017","unstructured":"Karatasakis A.; Danek B.A.; Karacsonyi J.; Rangan B.V.; Roesle M.K.; Knickelbine T.; Miedema M.D.; Khalili H.; Ahmad Z.; Abdullah S.; Banerjee S.; Brilakis E.S.; Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: A meta-analysis of 35 randomized controlled trials. J Am Heart Assoc 2017,6(12),e006910","journal-title":"J Am Heart Assoc"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"CD011748","DOI":"10.1002\/14651858.CD011748.pub2","volume":"4","author":"Schmidt AF","year":"2017","unstructured":"Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP; PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017,4(4),CD011748","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"8032978","DOI":"10.1155\/2021\/8032978","volume":"2021","author":"Ge X","year":"2021","unstructured":"Ge X; Zhu T; Zeng H; Yu X; Li J; Xie S; A systematic review and meta-analysis of therapeutic efficacy and safety of alirocumab and evolocumab on familial hypercholesterolemia. Biomed Res Int 2021,2021,8032978","journal-title":"Biomed Res Int"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230228120601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/214146\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230228120601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T10:59:27Z","timestamp":1695812367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/214146\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230228120601","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}